Customs duty cut, slash MRP of 3 cancer drugs, pharma companies told

The government instructed pharmaceutical companies to reduce prices on the anti-cancer drugs Trastuzumab, Osimertinib, and Durvalumab. This follows a Budget announcement on customs duty exemptions. The National Pharmaceutical Pricing Authority emphasizes that benefits from these tax reductions should directly reach consumers.